Latest:
Oncologists Play Many Roles in Lung Cancer Screening Programs
The role of the oncologist is essential to the design, operation, development and associate research of lung cancer screening programs.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Willem Overwijk, PhD
Latest:
Willem Overwijk Explains the Role of the Innate Immune System in Cancer Treatment
Willem Overwijk, PhD, Associate Professor, Department of Melanoma Medical Oncology, Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the role of innate immunity in the treatment of cancer.
William C. Huang, MD
William C. Huang, MD serves as the chief of the urology service at Tisch Hospital, NYU Langone Health in new York City.
Latest:
Dr Huang on the FDA Approval of Mitomycin Intravesical Solution for Recurrent, Low-Grade, Intermediate-Risk NMIBC
William C. Huang, MD, details the FDA approval of intravesical mitomycin for recurrent, low-grade, intermediate-risk non–muscle invasive bladder cancer.
William D. Tap, MD
William D. Tap, MD, chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center
Latest:
FDA Approval Insights: Vimseltinib for Symptomatic TGCT: With William D. Tap, MD
Dr Tap discusses the significance of this approval, key efficacy and safety data from the phase 3 MOTION trial, and the important role that multidisciplinary collaboration will play in integrating this therapy into clinical practice.
William F. Symmans, MB, ChB
Latest:
Dr. Symmans on Moon Shots Program for Patients With TNBC
William F. Symmans, MB, ChB, Division of Pathology/Lab Medicine, Department of Pathology, The University of Texas MD Anderson Cancer Center, discusses the institution's Moon Shots program for patients with triple-negative breast cancer.
William G Wierda, MD, University of Texas MD Anderson Cancer Center
Latest:
Rapid Readouts: Phase 1 Cohort of TRANSCEND-CLL-004 Study
William G. Wierda, MD, discusses data from the phase 1 cohort of lisocabtagene maraleucel combined with ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia that was presented at the 19th International Workshop on CLL (iwCLL) held in September 2021.